Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 43,783,120 | 43,100,480 | 41,139,870 | 38,903,720 | 37,797,960 |
| Cost of Goods | 15,027,940 | 15,147,860 | 13,669,690 | 13,328,770 | 12,590,740 |
| Gross Profit | 28,755,180 | 27,952,620 | 27,470,180 | 25,574,950 | 25,207,220 |
| Operating Expenses | 18,762,750 | 19,064,980 | 20,152,160 | 20,308,390 | 21,686,890 |
| Operating Income | 9,993,372 | 8,888,501 | 7,318,708 | 5,267,326 | 3,521,069 |
| Interest Expense | 1,145,328 | 1,164,533 | 1,065,170 | 945,979 | 997,501 |
| Other Income | 98,868 | 219,627 | 153,502 | 221,673 | 104,359 |
| Pre-tax Income | 8,946,912 | 7,943,595 | 6,407,040 | 4,543,020 | 2,627,927 |
| Income Tax | 744,720 | 1,216,886 | 1,006,439 | 1,747,613 | 1,188,598 |
| Net Income Continuous | 8,202,192 | 6,726,709 | 5,400,601 | 2,795,407 | 1,439,329 |
| Minority Interests | 820,476 | 795,509 | 564,620 | 820,966 | 203,295 |
| Net Income | $7,381,716 | $5,931,200 | $4,835,980 | $1,974,442 | $1,236,034 |
| EPS Basic Total Ops | 3.71 | 3.00 | 2.46 | 1.01 | 0.64 |
| EPS Basic Continuous Ops | 4.12 | 3.40 | 2.75 | 1.43 | 0.74 |
| EPS Diluted Total Ops | 3.66 | 2.96 | 2.43 | 1.00 | 0.63 |
| EPS Diluted Continuous Ops | 4.07 | 3.35 | 2.72 | 1.41 | 0.73 |
| EPS Diluted Before Non-Recurring Items | 3.73 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $13,012,050 | $11,868,790 | $9,796,096 | $7,744,402 | $5,925,369 |